Law360, The National Law Journal, Bloomberg Law and Global Legal Chronicle were among the legal news outlets that covered the arrival of Washington, D.C., partners Kevin Madagan and Clint Narver, who strengthen McGuireWoods’ capabilities in matters involving U.S. Food and Drug Administration regulated industries.
Madagan is an accomplished healthcare and FDA regulatory attorney who focuses on issues related to the development and commercialization of drugs, biologics, devices, combination products and dietary supplements. Narver is a former U.S. Department of Justice prosecutor and associate chief counsel at the FDA. He handles FDA regulatory and compliance issues and advises clients in connection with FDA-related investigations and enforcement actions.
In an Aug. 7, 2024, Law360 article, Madagan said: “I think our collective experience in enforcement and counseling and our subject matter expertise with respect to FDA adds an enormous value to McGuireWoods and clients at a time when the life sciences industry and investors face a sort of daunting combination of regulatory market and financial challenges.”
Narver added: “It was really a privilege to work in the offices I worked in, with the people I worked with. . . . [A]fter the amount of time [spent in government], I’ve become eager for new challenges and really interested in applying my experience and skill set in new ways.”